Neurology

 

Neurology

Advancing
CNS Biomarker Detection

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed.

Simoa assays can detect neurological biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS)  and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research.

Latest Publications

Quanterix' digital health solution, Simoa, is changing the way academics, researchers, scientists and drug manufacturers measure and detect Alzheimer's, Parkinsons' Disease, Traumatic Brain Injury (TBI) and concussions. Quanterix' focus in neurology and neurodegeneration is growing with a network of academic researchers and pharmaceutical and biotech partners. Learn about Simoa's advancements in detecting neurological biomarkers by exploring our scientific publications and journals.

Latest News

04.10
This study Investigates the association of plasma NFL with preclinical-AD features, such as high neocortical amyloid-β load (NAL) and subjective memory complaints, and cognitive performance in cognitively normal older adults.
04.09
The goals of the present study using a novel assay for pTau were to examine and compare levels of plasma phospho-tau181 (pTau181) and plasma total tau by clinical diagnosis across the AD spectrum